The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin.
Topical tazarotene has been shown to offer efficacy in ameliorating multiple effects of photodamage. ⋯ Treatment of photodamaged skin with tazarotene is associated with an amelioration of keratinocytic and melanocytic atypia, an improvement in epidermal polarity, and an increase in epidermal thickness.
-
Randomized Controlled Trial Clinical Trial
A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy.
Many patients find topical 5-aminolaevulinic acid (ALA) photodynamic therapy (PDT) painful. Local anaesthetics are not routinely used and their effect on PDT pain has not been examined. ⋯ When compared with placebo, tetracaine gel did not significantly reduce pain during or after PDT for small lesions of superficial basal cell carcinoma, Bowen's disease or actinic keratosis.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study.
Fexofenadine, a nonsedating, H1-receptor selective antihistamine, exhibits consistent efficacy and safety in the treatment of allergic rhinitis and urticaria. The pruritus associated with atopic dermatitis is considered to be induced, in part, by histamine. Therefore, we thought that fexofenadine may be useful in the relief of pruritus associated with atopic dermatitis. ⋯ Fexofenadine HCl 60 mg twice daily demonstrated a rapid, significant improvement in the pruritus associated with atopic dermatitis, with a safety profile equivalent to that of placebo.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch.
Renal itch is a relatively common and distressing problem for patients with chronic renal failure. Ondansetron, a serotonin type 3 receptor antagonist was developed for relief of chemotherapy induced nausea. Recently, anecdotal reports describe relief of renal itch with ondansetron. ⋯ Our results show that ondansetron is no better than placebo in controlling renal itch.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.
Botulinum toxin type A (BTX-A) has been shown to be a safe and effective treatment for primary focal hyperhidrosis. However, the effect of BTX-A therapy on quality of life (QOL) in patients with this condition has only recently begun to be studied in controlled clinical trials. ⋯ Hyperhidrosis is associated with a substantial QOL burden; however, QOL is markedly improved with BTX-A treatment.